Design Therapeutics (DSGN) Operating Expenses (2020 - 2026)

Design Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $22.2 million in Q2 2026.

• Operating Expenses for Q2 2026 came in at $22.2 million, up 2.82% year-over-year; the trailing twelve-month figure through Jun 2026 was $79.4 million (up 5.92% YoY), and the FY2025 annual result was $79.5 million, up 27.39% from the prior year.
• Operating Expenses climbed to $22.2 million in Q2 2026, from $19.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $22.6 million in Q2 2023 and troughed at $13.4 million in Q1 2022.
• A 5-year average of $18.3 million and a median of $19.0 million in 2022 frame the typical range for Operating Expenses.
• The widest annual swing landed in 2022, when Operating Expenses soared 135.39%; it then plunged 33.49% in 2024.
• A 5-year view of Operating Expenses shows it stood at $19.4 million in 2022, then declined by 22.02% to $15.1 million in 2023, then gained by 10.4% to $16.7 million in 2024, then grew by 8.84% to $18.2 million in 2025, then advanced by 22.06% to $22.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.2 million in Q2 2026, $19.7 million in Q1 2026, and $18.2 million in Q4 2025.